Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. HORIBA, Ltd.
  6. News
  7. Summary
    6856   JP3853000002

HORIBA, LTD.

(6856)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

HORIBA : Burkitt lymphoma - HORIBA Medical QSP Newsletter 16

09/03/2021 | 10:22am EDT

This edition talks about 'Burkitt's Lymphoma' which is one of the six cases released in QSP 2.0 in June 2021. Burkitt lymphoma (BL) is a rare type of Non-Hodgkin Lymphoma (NHL). BL develops when B-cells become abnormal (cancerous). B-cells are white blood cells that normally help fight infection. They are sometimes called B-lymphocytes... Download and read more on ►QSP Newsletter page

QSP Newsletter is based on the monthly case studies provided in HORIBA Medical's QSP 2.0 program for helping laboratories to update themselves quickly with important and unique real Hematology cases from around the world.

Disclaimer

Horiba Ltd. published this content on 03 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 September 2021 14:21:03 UTC.


© Publicnow 2021
All news about HORIBA, LTD.
10/20HORIBA : Technical Reports "Readout" No.55 is published
PU
10/19HORIBA : Acute myeloid leukemia type monoblastic (AML-M5b) - Clinical Cases of Yumizen...
PU
10/15HORIBA : Posted the presentation material for "SMBC Nikko Japan Series ESG Conference...
PU
10/15HORIBA : Posted the presentation material for "SMBC Nikko Japan Series ESG Conference Lond..
PU
10/14HORIBA : Veterinary haematology CPD webinar hosted by HORIBA to offer valuable best...
PU
10/06HORIBA : Development of the Partica CENTRIFUGE CN-300, Centrifugal Nanoparticle Analyzer ...
PU
10/04HORIBA : Scientific Validates the HORIBA Aqualog® Performance for Pharmaceutical...
PU
09/28VELODYNE LIDAR : Intelligent Traffic Monitoring Solution Chosen for Deployment at the Univ..
MT
09/28HORIBA : Sepsis and COVID - Clinical Cases of Yumizen H2500 Hematology Analyzers "Chase...
PU
09/16HORIBA : Scientific Partners with Covalent Metrology to Offer Glow Discharge...
PU
More news
Financials
Sales 2021 219 B 1 926 M 1 926 M
Net income 2021 20 269 M 179 M 179 M
Net cash 2021 37 969 M 335 M 335 M
P/E ratio 2021 15,8x
Yield 2021 1,78%
Capitalization 319 B 2 805 M 2 810 M
EV / Sales 2021 1,29x
EV / Sales 2022 1,22x
Nbr of Employees 8 269
Free-Float 91,6%
Chart HORIBA, LTD.
Duration : Period :
HORIBA, Ltd. Technical Analysis Chart | 6856 | JP3853000002 | MarketScreener
Technical analysis trends HORIBA, LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 7 560,00 JPY
Average target price 8 337,50 JPY
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Atsushi Horiba Chairman & Group Chief Executive Officer
Masayuki Adachi President & Representative Director
Sunao Kikkawa General Manager-Finance & Control Division
Juichi Saito Vice Chairman & Group Chief Operating Officer
Masao Okawa Managing Director & General Manager-Administration
Sector and Competitors
1st jan.Capi. (M$)
HORIBA, LTD.24.96%2 793
SMC CORPORATION7.61%38 334
COGNEX CORPORATION6.93%15 170
SHIMADZU CORPORATION15.34%11 981
MKS INSTRUMENTS, INC.-3.36%8 062
RENISHAW PLC-10.50%5 180